Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.

摘要: Epidermal growth factor receptor (EGFR) mutation status is the best predictor of patient response to treatments with tyrosine kinase inhibitors in primary lung adenocarcinoma and typically analyzed by DNA-based techniques, such as direct DNA sequencing allele-specific PCR. Recently, however, two mutation-specific antibodies against delE746-A750 exon 19 L858R 21 have opened door for a more convenient efficient strategy determine EGFR status. To evaluate clinical application new mouse monoclonal antibody (L858R), we performed immunohistochemistry (IHC) studies tumor samples from retrospective validation settings. A total 215 cases were examined compared using combination techniques (direct and/or PCR) protein-based IHC. IHC staining was assessed on 0 3+ score scale, cutoff value 2+ used positive In setting, statistical analyses data showed that sensitivity 90.9 % specificity 96.8 %. Findings study demonstrated 88.2 100 %, respectively. novel could be screening method assess adenocarcinoma.